The U.S. Food and Drug Administration is approving a growing number of applications from cannabis companies looking to conduct clinical trials studying medical marijuana. That development could lead to multiple cannabis-based medicines—including flower—receiving FDA approval to be commercialized and sold within the next five years.
The exodus of cannabis executives in Canada is in full swing after their companies raked up collective net losses exceeding CA$6 billion ($4.4 billion) in 2019, the first calendar year recreational products were allowed to be sold.
These comp tables provide a benchmark for private investors to evaluate existing and future investments, a way for companies to judge their own valuations for current and future capital raises as well as a menu for public investors to peruse.
Insurance reimbursements for medical cannabis in Germany reached a new high during the October-December period, propelling total reimbursements last year up nearly 70% from 2018, according to new data from the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Average trading multiples for U.S.-focused operators compressed this week, while Canada-focused operators still trade at a premium on sales compared to U.S. operators, despite a smaller market and lower margins.
These comp tables provide a benchmark for private investors to evaluate existing and future investments and a way for companies to judge their own valuations for current and future capital raises, as well as a menu for public investors to peruse.
Average trading multiples for U.S.-focused operators compressed this week, while Canada-focused operators still trade at a premium on sales compared to U.S. operators, despite a smaller market and lower margins.
Cannabis companies – both marijuana and hemp – were heating up the headlines this week. From Canada to Colorado and beyond, execs made big announcements and companies shifted gears.
Canadian companies are preparing to roll out cannabis-infused beverages to tap a market estimated to reach half-a-billion dollars.
British Columbia-based The Valens Co. announced the launch of a line of cannabis-infused beverages in Ontario this week, produced under a white label agreement with Iconic Brewing subsidiary A1 Cannabis Co.
New Canopy Growth CEO David Klein is already imposing discipline upon the Canadian market by closing a staggering 58% of the Ontario company’s existing indoor production capacity and 29% of its total production area.
